The pantoprazole patent, U.S. Patent No. 4,758,579, is owned by Nycomed and licensed to Wyeth(2), and expires in January 2011 (including pediatric exclusivity). Nycomed and Wyeth had filed their original patent infringement lawsuit in May 2004. In late 2007, Teva Pharmaceutical Industries Ltd., launched a generic version of the product at-risk, followed by Sun Pharmaceutical Industries Ltd., in early 2008.
About Protonix(R) (Pantoprazole)
Protonix(R) (Pantoprazole) is a proton pump inhibitor (PPI) used to reduce or prevent the production of gastric acid. Pantoprazole is an effective treatment for conditions where gastric acid reduction is required. It reduces the symptoms of a number of illnesses including stomach and intestinal gastric ulcers, heartburn, Gastro-esophageal Reflux Disease (GERD), and other related gastrointestinal diseases. Pantoprazole is also effective in preventing NSAID-induced gastric ulcers and is used by patients undergoing long-term NSAID therapy.
Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.
Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.
Nycomed employs 12,000 associates worldwide, and its products are
available in more than
Copyright©2010 PR Newswire.
All rights reserved